Amylyx Pharmaceuticals, Inc. (AMLX)
NASDAQ: AMLX · Real-Time Price · USD
4.050
+0.090 (2.27%)
At close: Dec 20, 2024, 4:00 PM
4.060
+0.010 (0.25%)
After-hours: Dec 20, 2024, 4:26 PM EST
Amylyx Pharmaceuticals Revenue
Amylyx Pharmaceuticals had revenue of $416.00K in the quarter ending September 30, 2024, a decrease of -99.59%. This brings the company's revenue in the last twelve months to $196.49M, down -33.22% year-over-year. In the year 2023, Amylyx Pharmaceuticals had annual revenue of $380.79M with 1,612.94% growth.
Revenue (ttm)
$196.49M
Revenue Growth
-33.22%
P/S Ratio
1.40
Revenue / Employee
$511,680
Employees
384
Market Cap
275.73M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 380.79M | 358.56M | 1,612.94% |
Dec 31, 2022 | 22.23M | 21.95M | 7,700.00% |
Dec 31, 2021 | 285.00K | -365.00K | -56.15% |
Dec 31, 2020 | 650.00K | -776.00K | -54.42% |
Dec 31, 2019 | 1.43M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Accolade | 441.03M |
Procaps Group | 414.10M |
Zynex | 193.67M |
Vanda Pharmaceuticals | 190.86M |
Sanara MedTech | 78.06M |
C4 Therapeutics | 33.67M |
ProQR Therapeutics | 20.51M |
Sera Prognostics | 94.00K |
AMLX News
- 3 days ago - Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Amylyx Pharmaceuticals, Inc. (AMLX) And Encourages Investors to Reach Out - Accesswire
- 6 days ago - Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Amylyx Pharmaceuticals, Inc. (AMLX) And Encourages Stockholders to Reach Out - Accesswire
- 10 days ago - Bronstein, Gewirtz & Grossman, LLC Is Investigating Amylyx Pharmaceuticals, Inc. (AMLX) And Encourages Stockholders to Connect - Accesswire
- 17 days ago - Amylyx Pharmaceuticals Announces Pivotal Phase 3 LUCIDITY Trial Design for GLP-1 Receptor Antagonist (Avexitide) in Post-Bariatric Hypoglycemia - Business Wire
- 24 days ago - Amylyx Pharmaceuticals to Present at the 7th Annual Evercore ISI HealthCONx Conference - Business Wire
- 26 days ago - Amylyx: AMX0035 PSP Data In Mid-2025 Is Just One Program Moving Along - Seeking Alpha
- 4 weeks ago - Best Cheap Stocks To Buy Now (Under $10) - Kiplinger
- 6 weeks ago - Amylyx Pharmaceuticals, Inc. (AMLX) Q3 2024 Earnings Call Transcript - Seeking Alpha